Document is current
Any future updates will be listed below
-
Authors
LaHue, Sara C.
Takegami, Naoki
Simmasalam, Rubinee
Baqai, Abiya
Munoz, Elena
Sikri, Anya
de Courson, Thibault du Buisson
Singhal, Nilika S.
Eckalbar, Walter
Langelier, Charles R.
Hendrickson, Carolyn M.
Calfee, Carolyn S.
Erle, David J.
Krummel, Matthew F.
Woodruff, Prescott G.
Oskotsky, Tomiko
Sirota, Marina
Ferguson, Adam
Douglas, Vanja C.
Newman, John C.
Pleasure, Samuel J.
Wilson, Michael R.
Singhal, Neel S. https://orcid.org/0000-0003-1605-4444
-
Funding
Funding for this research was provided by:
NIH (U19AI077439)
NIH (R01NS125693)
Chan Zuckerberg Initiative (2019-202665)
Genentech Foundation (TSK-020586)
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 8 September 2025
First Online: 22 September 2025
Declarations
:
: Patients, or a designated surrogate, provided informed consent to participate in the study in accordance with protocols approved by the Institutional Review Board of UCSF and ZSFG (#20–30497).
: Not applicable.
: CSC has served as a scientific advisor for Vasomune and Quark Pharmaceuticals and has received funding from Roche/Genentech. CMH has provided paid consulting services to Spring Discovery for planning clinical trials related to the treatment of COVID-19 disease and the acute respiratory distress syndrome unrelated to the topics addressed in this manuscript.
